CytRx Corporation (NASDAQ: CYTR), located in Los Angeles, California, is a clinical-stage, biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer.
CytRx's initial focus is on seeking regulatory approval for and commercialization of our lead drug candidate, aldoxorubicin, an improved version of the widely used chemotherapeutic agent doxorubicin. Aldoxorubicin is currently in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, and is also being evaluated in several other cancer indications with significant unmet clinical need, including small-cell lung cancer.
CytRx plans to expand its pipeline of oncology candidates using its Linker Activated Drug Release, or LADR™, technology platform. Our LADR research efforts currently center on creating new molecules from the combination of ultra high potency cytotoxic payloads with novel, tunable linkers.